<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819180</url>
  </required_header>
  <id_info>
    <org_study_id>FLU-02-IB</org_study_id>
    <nct_id>NCT02819180</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB</brief_title>
  <acronym>FLU-02-IB</acronym>
  <official_title>Prospective Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective cohort study to evaluate the safety and immunogenicity of the Butantan Influenza
      vaccine (Fragmented and Inactivated) among healthy adults with 18 to 59 years of age and
      elderly older than 60 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective cohort study to assess safety of one dose of theButantan Influenza vaccine
      (Fragmented and Inactivated) in the first 3 days after vaccination and its immunogenicity 21
      days after vaccination among healthy adults with 18 to 59 years of age and elderly older than
      60 years of age..
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events in the first 3 days post vaccination (Safety)</measure>
    <time_frame>Three days</time_frame>
    <description>Solicited and unsolicited local and systemic adverse reactions reported by the participants until Day 3 after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody response to each of the vaccine strains 21 days post vaccination (Immunogenicity)</measure>
    <time_frame>21 days</time_frame>
    <description>Antibody response to each of the vaccine´s strains as measured by:
% seroconversion and/or
increase in the geometric mean of hemagglutination inhibition (HAI) titers and/or
% seroprotection.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Healthy adults group</arm_group_label>
    <description>Healthy men and women between 18 and 59 years of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly group</arm_group_label>
    <description>Elderly over 60 years old.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Butantan Influenza Trivalent, Fragmented and Inactivated vaccine</intervention_name>
    <arm_group_label>Healthy adults group</arm_group_label>
    <arm_group_label>Elderly group</arm_group_label>
    <other_name>Butantan Influenza vaccine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Health adults with age between 18 and 59 years, as well as elderly over 60 years of age may
        participate in the study. To be included in the study, participants need to meet all
        inclusion criteria, and not fulfill any exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults, male or female aged 18 to 59

          -  Elderly aged 60 years completed and above

          -  To be available to participate in the study throughout its duration (approximately 21
             days)

          -  To have medical indication to be vaccinated against influenza

          -  To demonstrate intention to participate in the study, as documented by signature in
             the study´s informed consent form.

        Exclusion Criteria:

          -  Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as
             clinical history and/or physical examination (except hypertension under control among
             the elderly)

          -  Compromised immune system diseases including: HIV, diabetes mellitus, cancer (except
             basal cell carcinoma) and autoimmune diseases

          -  Behavioral, cognitive or psychiatric disease that in the opinion of the principal
             investigator or his representative physician, affects the participant ability to
             understand and cooperate with all study protocol requirements

          -  Abusive usage of alcohol or drugs in the past 12 months that has caused medical,
             professional or family problems, indicated by clinical history

          -  Known systemic hypersensitivity to eggs or to any component of the vaccine

          -  History of severe adverse reaction after previous administration of an Influenza
             vaccine within 6 weeks following vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro de Referência de Imunobiológicos Especiais (CRIE) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

